Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1937 1
1987 5
1988 11
1989 10
1990 9
1991 6
1992 12
1993 10
1994 9
1995 11
1996 10
1997 19
1998 15
1999 16
2000 12
2001 9
2002 9
2003 14
2004 18
2005 10
2006 19
2007 20
2008 22
2009 26
2010 19
2011 16
2012 18
2013 30
2014 33
2015 40
2016 51
2017 44
2018 60
2019 55
2020 65
2021 74
2022 79
2023 71
2024 85
2025 94
2026 51

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,057 results

Results by year

Filters applied: . Clear all
Page 1
AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis.
Singh S, Loftus EV Jr, Limketkai BN, Haydek JP, Agrawal M, Scott FI, Ananthakrishnan AN; AGA Clinical Guidelines Committee. Electronic address: clinicalpractice@gastro.org. Singh S, et al. Gastroenterology. 2024 Dec;167(7):1307-1343. doi: 10.1053/j.gastro.2024.10.001. Gastroenterology. 2024. PMID: 39572132 Free PMC article.
BACKGROUND & AIMS: This American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the pharmacological management of moderate-to-severe ulcerative colitis (UC). METHODS: A multidisciplinary panel of content experts an …
BACKGROUND & AIMS: This American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the phar …
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.
Ananthakrishnan AN, Murad MH, Scott FI, Agrawal M, Haydek JP, Limketkai BN, Loftus EV Jr, Singh S. Ananthakrishnan AN, et al. Gastroenterology. 2024 Dec;167(7):1460-1482. doi: 10.1053/j.gastro.2024.07.046. Epub 2024 Oct 18. Gastroenterology. 2024. PMID: 39425738 Free PMC article.
BACKGROUND & AIMS: We performed an updated systematic review and network meta-analysis to inform the 2024 American Gastroenterological Association (AGA) Clinical Guidelines on the management of moderate-to-severe ulcerative colitis (UC). METHODS: We searched mul …
BACKGROUND & AIMS: We performed an updated systematic review and network meta-analysis to inform the 2024 American Gastroenterological A …
Medical management of inflammatory bowel diseases.
Hashash JG, Limdi JK, Shapiro JM, Shah SA. Hashash JG, et al. BMJ. 2025 Dec 19;391:e079050. doi: 10.1136/bmj-2025-079050. BMJ. 2025. PMID: 41419296 Review.
Inflammatory bowel diseases (IBD), comprising Crohn's disease and ulcerative colitis, are chronic, inflammatory, immune mediated, relapsing-remitting conditions of the gastrointestinal tract with multidimensional and often negative effects on patients' quality of li …
Inflammatory bowel diseases (IBD), comprising Crohn's disease and ulcerative colitis, are chronic, inflammatory, immune mediat …
Upadacitinib for Acute Severe Ulcerative Colitis: A Systematic Review.
Damianos JA, Osikoya O, Brennan G. Damianos JA, et al. Inflamm Bowel Dis. 2025 Apr 10;31(4):1145-1149. doi: 10.1093/ibd/izae191. Inflamm Bowel Dis. 2025. PMID: 39186564 Free article.
Acute severe ulcerative colitis (ASUC) remains a clinical challenge associated with considerable morbidity, including colectomy. Upadacitinib (UPA), a selective Janus kinase (JAK)-1 inhibitor, is approved for moderate-to-severe ulcerative colitis in pa …
Acute severe ulcerative colitis (ASUC) remains a clinical challenge associated with considerable morbidity, including colectom …
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, Vetrano S, Vande Casteele N. Salas A, et al. Nat Rev Gastroenterol Hepatol. 2020 Jun;17(6):323-337. doi: 10.1038/s41575-020-0273-0. Epub 2020 Mar 19. Nat Rev Gastroenterol Hepatol. 2020. PMID: 32203403 Review.
The biological effects of cytokines, including several involved in the pathology of Crohn's disease and ulcerative colitis, occur as a result of receptor-mediated signalling through the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) D …
The biological effects of cytokines, including several involved in the pathology of Crohn's disease and ulcerative colitis, oc …
Monitoring Inflammatory Bowel Disease Activity: When, How, and Why.
Gaidos JKJ, Hashash JG. Gaidos JKJ, et al. Am J Gastroenterol. 2025 Jun 9;120(8):1732-1741. doi: 10.14309/ajg.0000000000003582. Am J Gastroenterol. 2025. PMID: 40488637 Review.
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, are disorders caused by inflammation in the gastrointestinal tract leading to a wide variety of symptoms. ...
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, are disorders caused by inflammation in th …
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Schroeder KW, Tremaine WJ, Ilstrup DM. Schroeder KW, et al. N Engl J Med. 1987 Dec 24;317(26):1625-9. doi: 10.1056/NEJM198712243172603. N Engl J Med. 1987. PMID: 3317057 Clinical Trial.
We assessed oral 5-aminosalicylic acid (5-ASA) prepared with a pH-sensitive polymer coating in 87 patients with mildly to moderately active ulcerative colitis in a double-blind, placebo-controlled trial. Patients were randomly assigned to receive 5-ASA at a dosage o …
We assessed oral 5-aminosalicylic acid (5-ASA) prepared with a pH-sensitive polymer coating in 87 patients with mildly to moderately active …
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. Singh S, et al. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2179-2191.e6. doi: 10.1016/j.cgh.2020.01.008. Epub 2020 Jan 13. Clin Gastroenterol Hepatol. 2020. PMID: 31945470 Free PMC article.
BACKGROUND & AIMS: We compared the efficacy and safety of different first-line (biologic-naive) and second-line (prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moderate to severely active ulcerative colitis in a systematic rev …
BACKGROUND & AIMS: We compared the efficacy and safety of different first-line (biologic-naive) and second-line (prior exposure to tumor …
Anti-Integrin alphavbeta6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis.
Livanos AE, Dunn A, Fischer J, Ungaro RC, Turpin W, Lee SH, Rui S, Del Valle DM, Jougon JJ, Martinez-Delgado G, Riddle MS, Murray JA, Laird RM, Torres J, Agrawal M, Magee JS, Dervieux T, Gnjatic S, Sheppard D, Sands BE, Porter CK, Croitoru K, Petralia F; CCC-GEM Project Research Consortium; OSCCAR Consortium; Colombel JF, Mehandru S. Livanos AE, et al. Gastroenterology. 2023 Apr;164(4):619-629. doi: 10.1053/j.gastro.2022.12.042. Epub 2023 Jan 10. Gastroenterology. 2023. PMID: 36634824 Free PMC article.
BACKGROUND & AIMS: Better biomarkers for prediction of ulcerative colitis (UC) development and prognostication are needed. Anti-integrin alphavbeta6 (anti-alphavbeta6) autoantibodies have been described in patients with UC. ...In a distinct, external validation …
BACKGROUND & AIMS: Better biomarkers for prediction of ulcerative colitis (UC) development and prognostication are needed. …
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
Loftus EV Jr, Colombel JF, Takeuchi K, Gao X, Panaccione R, Danese S, Dubinsky M, Schreiber S, Ilo D, Finney-Hayward T, Zhou W, Phillips C, Gonzalez YS, Shu L, Yao X, Zhou Q, Vermeire S. Loftus EV Jr, et al. Clin Gastroenterol Hepatol. 2023 Aug;21(9):2347-2358.e6. doi: 10.1016/j.cgh.2022.11.029. Epub 2022 Dec 1. Clin Gastroenterol Hepatol. 2023. PMID: 36464141 Free article.
BACKGROUND & AIMS: We evaluated the efficacy of once-daily (QD) upadacitinib 45 mg, an oral, reversible Janus kinase inhibitor, on early symptomatic improvement for ulcerative colitis (UC). Post hoc analyses were performed on pooled data from 2 replicate, phase …
BACKGROUND & AIMS: We evaluated the efficacy of once-daily (QD) upadacitinib 45 mg, an oral, reversible Janus kinase inhibitor, on early …
1,057 results